The Next Wave: Bringing Order to Disorder

Around a third of the proteins in the human body are IDPs and are structurally labile in whole or in part, assuming different shapes and forms depending on their cellular context. With no fixed structure when isolated, they are not amenable to classical drug discovery methods, and their underlying genetic sequences cannot accurately predict their structural properties. Consequently, efforts to find and develop rigidly designed drugs that will target and bind these proteins are likely to fail.
By combining experimental biophysics, atomic-level experimental approaches, high-performance supercomputing (HPC) and machine learning (ML), Peptone is unlocking the potential of IDPs and pioneering the development of novel therapeutics against this entirely new class of high-value and previously undruggable targets.